Mr. Dwight Gorham reports

INTELGENX LAUNCHES PREFERRED SHARE REGULATION A OFFERING

IntelGenx Corp. has launched a Regulation A offering of up to two million shares of Series A convertible cumulative preferred stock (with a par value 0.001 cent per share) at an offering price of $10 per share for a maximum offering amount of $20-million.

Holders of the Series A preferred stock will be entitled to receive cumulative dividends in the amount of 20 cents per share each quarter, or 8 per cent per year. Each share of Series A preferred stock will be convertible into 20 shares of the company's common stock at the option of the holder, subject to certain conditions in accordance with the requirements of the Toronto Stock Exchange. Commencing on the fifth anniversary of the initial closing of this offering and continuing indefinitely thereafter, the company shall have a right to call for redemption the outstanding shares of the Series A preferred stock at a call price equal to 150 per cent of the original issue price of the Series A preferred stock, and, correspondingly, each holder of shares of the Series A preferred stock shall have a right to sell the shares of Series A preferred stock held by such holder back to the company at a price equal to 150 per cent of the original issue purchase price of such shares. The Series A preferred stock being offered will rank, as to dividend rights and rights upon the company's liquidation, dissolution or winding up, senior to the common stock.

"We are excited to launch this offering of non-traded preferred shares to allow the company to raise funds at a valuation that we believe is more reflective of our assets and business prospects," stated Dwight Gorham, IntelGenx's chief executive officer. "With the pending U.S. commercial launch of RizaFilm, which we continue to expect to occur in the second quarter, we will be entering into a phase of anticipated rapid growth. This raise will allow us to support that while we also continue to make strategic investments in the advancement of the rest of our product pipeline and services portfolio."

Digital Offering LLC is acting as the sole lead managing selling agent for the offering in the United States.

In the United States, the offering is being made pursuant to Regulation A under the U.S. Securities Act of 1933, as amended, and as a private placement in all provinces and territories of Canada, except Quebec. An offering statement on Form 1-A, as amended, relating to these securities has been filed with the U.S. Securities and Exchange Commission and has been qualified. A copy of the preliminary offering circular that forms a part of the offering statement is available on the company's EDGAR profile

The company intends to use the net proceeds of the offering for product launches, debt repayment and working capital purposes. The offering is subject to receipt of all necessary approvals, including approval of the TSX.

About IntelGenx Technologies Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including R&D (research and development), analytical method development, clinical monitoring, and IP (intellectual property) and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot-scale and commercial-scale production.

We seek Safe Harbor.